Gen Wealth Partners Inc Buys 86 Shares of Becton, Dickinson and Company (NYSE:BDX)

Gen Wealth Partners Inc boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,553 shares of the medical instruments supplier’s stock after purchasing an additional 86 shares during the quarter. Gen Wealth Partners Inc’s holdings in Becton, Dickinson and Company were worth $806,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $25,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company in the 4th quarter worth about $29,000. Picton Mahoney Asset Management raised its holdings in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 54 shares in the last quarter. Hopwood Financial Services Inc. bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $39,000. Finally, CoreFirst Bank & Trust purchased a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.4 %

BDX opened at $167.22 on Friday. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $208.84 and its 200-day moving average price is $223.15. The company has a market cap of $48.01 billion, a P/E ratio of 27.78, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the firm earned $3.17 EPS. The business’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.49%. Becton, Dickinson and Company’s payout ratio is currently 79.39%.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research analyst reports. Barclays decreased their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating on the stock in a report on Monday, April 7th. Piper Sandler lowered shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Bank of America downgraded Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target on the stock. in a research report on Thursday, May 1st. Wells Fargo & Company cut Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Finally, StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $231.44.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 700 shares of the stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the business’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the transaction, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,578 shares of company stock valued at $795,986 in the last quarter. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.